Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA alphavaccine
- Development stage
- Unknown
- Lead developer
- AlphaVax
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
PSMA alphavaccine (AVX-501) is an experimental cancer vaccine developed by AlphaVax, in collaboration with Progenics Pharmaceuticals and PSMA Development Company, for the treatment of prostate cancer. The vaccine utilizes the Venezuelan Equine Encephalitis (VEE) virus-based replicon particle (VRP) platform. In this system, the structural genes of the VEE virus are replaced with the gene encoding prostate-specific membrane antigen (PSMA), a protein highly expressed on the surface of prostate cancer cells. These single-cycle, self-replicating RNA particles are designed to infect dendritic cells and induce high-level expression of PSMA, thereby triggering both cellular (T-cell) and humoral (antibody) immune responses against the tumor. Clinical evaluation has reached Phase I in patients with metastatic castration-resistant prostate cancer, where it demonstrated good tolerability but modest immunogenicity at the doses tested.
- Other names
- AlphaVax PSMA vaccinePSMA VRP vaccineVEE-PSMA replicon vaccine
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on PSMA alphavaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSMA alphavaccine.